Pharmacy Operational Update

Medpal AI PLC

16 March 2026

 

16 March 2026

MedPal AI plc

("MedPal AI" or the "Company")

Pharmacy - Operational Update

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to provide an operational update on pharmacy dispensing volumes at its wholly-owned subsidiary, MedPal Limited.

MedPal AI combines its user-friendly mobile app, AI-driven diagnosis and triage with human-in-the-loop clinical oversight and prescribing services, with high-tech robotic pharmacy dispensing.

Dispensing Performance

Since the launch of pharmacy operations at the Company's national distribution centre in November 2025, MedPal Limited has dispensed a total of almost 147,000 prescription items in the first four months of operations, generating turnover in the period in excess of £1.5 million.

The average gross margin across the period was approximately 33%, reflecting the Company's efficient, technology-driven fulfilment model and favourable unit economics as prescription volumes continue to scale.

In February 2026, the Company dispensed 32,637 items, maintaining a strong level of activity and continuing to support monthly pharmacy revenue in excess of £300,000.

This sustained growth in dispensing volumes further demonstrates the effectiveness of the Company's advanced AI triage system and state-of-the-art robotic dispensing infrastructure, together with increasing patient demand for both NHS and private prescription services, including through the MedPal.clinic weight-loss platform

Jason Drummond, CEO of MedPal AI, said:

"Dispensing nearly 147,000 prescription items and generating turnover in excess of £1.5 million in our first four months of pharmacy operations is an outstanding achievement for the Company. This performance validates the scalability and commercial viability of our automated dispensing model and the strength of our vertically integrated platform.

"We continue to see strong demand across both our NHS Distance Selling Pharmacy contract and our private weight-loss services through MedPal.clinic, and we look forward to updating the market on continued progress."

Enquiries:

MedPal AI plc Jason Drummond, Chief Executive Officer	Via Square1 Consulting
Cairn Financial Advisers LLP        Louise O'Driscoll/Jo Turner	[phone]
Clear Capital Markets Limited Bob Roberts	[phone]
Square1 Consulting David Bick	[phone] [phone]

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

 

END